SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”...
Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent...
Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by...
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a...
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads